MTOR and neuroblastoma: Therefore, targeted therapies using PI3K/Akt/mTOR inhibitors, anti-angiogenic drugs and ALK antagonists are in phase I/II clinical trials either alone or in combination with conventional chemotherapy for refractory or recurrent NB [6].